Elicityl

912 Safety Data Sheets and Chemical Risk Assessments supplied by Elicityl.

• Blood Group H Antigen Triose Type 5 / 2-Fucosyllactose (2'-FL) With Cyclic Di-Thiol (Linker-LIPO A)
• Blood Group H Antigen Triose Type 5 / 2-Fucosyllactose (2'-FL) With DBCO (Linker-DBCO A)
• Blood Group H Antigen Triose Type 5 / 2-Fucosyllactose (2'-FL) With Free Terminal Amine (Linker-NH2 A)
• Blood Group H Antigen Triose Type 5 / 2-Fucosyllactose (2'-FL) With Free Terminal Amine (Linker-NH2 B)
• Blood Group H Antigen Triose Type 5 / 2-Fucosyllactose (2'-FL) With Free Terminal Amine (Linker-NH2 C)
• Blood Group H Antigen Triose Type 5 / 2-Fucosyllactose (2'-FL) With Free Terminal Amine (Linker-NH2 D)
• Blood Group H Antigen Triose Type 5 / 2-Fucosyllactose (2'-FL) With Free Terminal Amine (Linker-NH2 E)
• Blood Group H Antigen Triose Type 5 / 2-Fucosyllactose (2'-FL) With Stearic Chain (Linker-STEA A)
• Blood Group H Antigen Triose Type 5 / 2-Fucosyllactose (2'-FL) With Terminal Alkyne (Linker-C=CH A)
• Blood Group H Antigen Triose Type 5 / 2-Fucosyllactose (2'-FL) With Terminal Alkyne (Linker-C=CH B)
• Blood Group H Antigen Triose Type 5 / 2-Fucosyllactose (2'-FL) With Terminal Alkyne (Linker-C=CH C)
• Blood Group H Antigen Triose Type 5 / 2-Fucosyllactose (2'-FL) With Terminal Azide (Linker-N3 A)
• Blood Group H Antigen Triose Type 5 / 2-Fucosyllactose (2'-FL) With Terminal Azide (Linker-N3 B)
• Cellobiose (>95% HPAEC-PAD)
• Cellohexaose (>80% HPAEC-PAD)
• Cellooctaose (>90% HPAEC-PAD)
• Cellopentaose (>95% HPAEC-PAD)
• Cellotetraose (>95% HPAEC-PAD)
• Cellotriose (>95% HPAEC-PAD)
• Chitin Polysaccharide
• Chitinheptaose DP7 (>90% NMR)
• Chitinhexaose DP6 (>90% RMN)
• Chitinpentaose DP5 (>85% RMN)
• Chitintetraose DP4 (>85% RMN)
• Chitosan Oligosaccharides Average DP24
• Chitosan Oligosaccharides Average DP40
• Chitosan Oligosaccharides Average DP6
• Chitosan Oligosaccharides Average DP60
• Core Type 1 Triose (>90% NMR)
• Core Type 1 Triose Grafted On CRM197
• Core Type 1 Triose Grafted On KLH
• Core Type 1 Triose Grafted On OVA
• Core Type 1 Triose Linked To Biotin (Linker-BT B)
• Core Type 1 Triose Linked To Biotin (Linker-BT C)
• Core Type 1 Triose Linked To Desthiobiotin (Linker-DBT-A)
• Core Type 1 Triose Linked To Maleimide (Linker-MAL A)
• Core Type 1 Triose With Customizable Dual Functionalization
• Core Type 1 Triose With Cyclic Di-Thiol (Linker-LIPO A)
• Core Type 1 Triose With DBCO (Linker-DBCO A)
• Core Type 1 Triose With Free Terminal Amine (Linker-NH2 D)
• Core Type 1 Triose With Stearic Chain (Linker-STEA A)
• Core Type 1 Triose With Terminal Azide (Linker-N3 A)
• Core Type 1 Triose With Terminal Azide (Linker-N3 B)
• Core Type 2 Triose (>90% NMR)
• Core Type 2 Triose Grafted On BSA
• Core Type 2 Triose Grafted On Gel For Affinity Chromatography (Linker-GEL B)
• Core Type 2 Triose Grafted On HSA
• Core Type 2 Triose Grafted On KLH
• Core Type 2 Triose Grafted On OVA
• Core Type 2 Triose Linked To Biotin (Linker-BT A)
• Core Type 2 Triose Linked To Biotin (Linker-BT B)
• Core Type 2 Triose With Customizable Dual Functionalization
• Core Type 2 Triose With Cyclic Di-Thiol (Linker-LIPO A)
• Core Type 2 Triose With Free Terminal Amine (Linker-NH2 C)
• Core Type 2 Triose With Free Terminal Amine (Linker-NH2 D)
• Core Type 2 Triose With Terminal Azide (Linker-N3 B)
• Core Type 4 (Gb5 Triose Core Structure) Grafted On BSA
• Core Type 4 (Gb5 Triose Core Structure) Grafted On OVA
• Core Type 4 (Gb5 Triose Core Structure) Linked To Biotin (Linker-BT A)
• Core Type 4 (Gb5 Triose Core Structure) With Free Terminal Amine (Linker-NH2 B)
• Core Type 4 (Gb5 Triose Core Structure) With Free Terminal Amine (Linker-NH2 C)
• Core Type 4 (GbS Triose Core Structure) Linked To Biotin (Linker-BT B)
• Core Type 4 (GbS Triose Core Structure) Linked To Biotin (Linker-BT C)
• Core Type 4 (GbS Triose Core Structure) Linked To Maleimide (Linker-MAL A)
• Core Type 4 (GbS Triose Core Structure) With Cyclic Di-Thiol (Linker-LIPO A)
• Core Type 4 (GbS Triose Core Structure) With Free Terminal Amine (Linker-NH2 A)
• Core Type 4 (GbS Triose Core Structure) With Free Terminal Amine (Linker-NH2 D)
• Core Type 4 (GbS Triose Core Structure) With Stearic Chain (Linker-STEA A)
• Core Type 4 (GbS Triose Core Structure) With Terminal Azide (Linker-N3 A)
• Curdlan Polysaccharide
• Di-N-Acetyl-D-Lactosamine (>90% NMR)
• Di-N-Acetyl-D-Lactosamine Grafted On CRM197
• Difucosyllactose (DF-L) Analytical Reference
• Difucosyllactose (DFL) / Lactodifucotetraose (>90% NMR)
• Disialosylpentaose (>90% NMR)
• Disialylated Pentaose Type 1 (>85% NMR)
• Disialylated Pentaose Type 1 Grafted On CRM197
• Disialylated Pentaose Type 1 Grafted On HSA
• Disialylated Pentaose Type 1 Grafted On KLH
• Disialylated Pentaose Type 1 Linked To Biotin (Linker-BT B)
• Disialylated Pentaose Type 1 Linked To Biotin (Linker-BT C)
• Disialylated Pentaose Type 1 Linked To Biotin And Fluorescein (Linker-BT-FLUO A)
• Disialylated Pentaose Type 1 Linked To Biotin And Stearic Chain (Linker-BT-STEA A)
• Disialylated Pentaose Type 1 Linked To Maleimide (Linker-MAL A)
• Disialylated Pentaose Type 1 With Cyclic Di-Thiol (Linker-LIPO A)
• Disialylated Pentaose Type 1 With DBCO (Linker-DBCO A)
• Disialylated Pentaose Type 1 With Stearic Chain (Linker-STEA A)
• Disialylated Pentaose Type 1 With Terminal Alkyne (Linker-CCH A)
• Disialylated Pentaose Type 1 With Terminal Alkyne (Linker-CCH B)
• Disialylated Pentaose Type 1 With Terminal Alkyne (Linker-CCH C)
• Disialylated Pentaose Type 1 With Terminal Azide (Linker-N3 A)
• Forssman Antigen Pentaose (>90% NMR)
• Forssman Antigen Triose (>90% NMR)
• Fructo-Oligosaccharide DP11 / GF10 (>70% HPAEC-PAD)
• Fructo-Oligosaccharide DP12 / GF11 (>90% HPAEC-PAD)
• Fructo-Oligosaccharide DP5 / GF4 (>95% HPAEC-PAD)
• Fructo-Oligosaccharide DP6 / GF5 (>95% HPAEC-PAD)
• Fructo-Oligosaccharide DP7 / GF6 (>95% HPAEC-PAD)
• Fructo-Oligosaccharide DP8 / GF7 (>95% HPAEC-PAD)
• Fructo-Oligosaccharide DP9 / GF8 (>95% HPAEC-PAD)